The FDA-approved PD-1/PD-L1 immunotherapies currently include treatments for lung cancer, colorectal cancer, TNBC, and other malignancies (Lee et al., 2020; Nobin et al., 2024; Savic et al., 2019). This evidence concerns the gene CD274 and colorectal cancer.